Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary About 20% of Americans taking a GLP-1 for weight loss are not using an FDA-approved product, according to a recent Gallup survey. Another 12% were unsure what they were
Summary Biogen announced a $1 billion buyout of RayThera, a secretive immunology startup, on June 18, 2026. The deal is expected to close in Q3 2026. RayThera’s pipeline includes TNF
On June 8, 2026, Roche and Nurix Therapeutics announced a clinical collaboration for bexobrutideg — a BTK protein degrader in development for chronic lymphocytic leukemia and other blood cancers. Roche
We have just published a MARA Rating for a one-time gene therapy for a rare childhood disease. The trials answered one question clearly: do treated patients do better than untreated
Summary Eli Lilly has given hospitals in the 340B drug discount program until Monday, June 9, 2026, to comply with data sharing requirements — or lose access to 340B pricing
This week we finished a MARA Rating for a treatment for idiopathic pulmonary fibrosis — a progressive lung disease with limited options. The Phase 3 trial answered one question clearly:
Executive Summary MARA is currently finalizing a series of reimbursement risk assessments across twelve drug–indication pairs spanning oncology, rare diseases, immunology, nephrology, and cardiovascular conditions. These assessments have been initiated